Physician profile
Mary Rayborn
NPI 1992865828
$1,610.06
in general payments reported to CMS, 2019-2025
24 companies · $468 in 2025
The $468 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $331 · 2023: $472 · 2024: $339 · 2025: $468.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,279.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,279.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $303.64 | 2022-2025 | |
| Novo Nordisk INC | $227.22 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $204.50 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $163.84 | 2022-2025 | Breztri, Farxiga |
| Glaxosmithkline, LLC. | $81.54 | 2022-2024 | Shingrix |
| Lundbeck LLC | $65.27 | 2023-2025 | Rexulti |
| Abbott Laboratories | $65.08 | 2023-2025 | Freestyle Libre |
| Pfizer INC. | $60.30 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $51.43 | 2023-2025 | Trintellix |
| Amgen INC. | $49.62 | 2022-2024 | Otezla, Repatha |
| Astellas Pharma US INC | $39.38 | 2023 | Veozah |
| Exact Sciences Corporation | $33.27 | 2023-2025 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.61 | 2022-2025 | Jardiance |
| Dexcom, INC. | $29.62 | 2022-2023 | Dexcom G6 Transmitter |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $28.84 | 2025 | Caplyta |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $26.85 | 2025 | Auvelity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $26.03 | 2022-2023 | Xifaxan |
| Viatris Specialty LLC | $21.62 | 2025 | Yupelri |
| Xeris Pharmaceuticals, INC. | $21.03 | 2025 | Gvoke Hypopen |
| Phathom Pharmaceuticals, INC. | $20.43 | 2024 | Voquezna |
| Novartis Pharmaceuticals Corporation | $16.34 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $14.62 | 2022 | |
| Organon LLC | $14.25 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.73 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Rayborn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.